At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 328 enrolled
Drug / intervention
Azilsartan medoxomil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension
In Brief
A Phase 3 clinical trial evaluating Azilsartan medoxomil and Azilsartan medoxomil placebo for Hypertension. Completed, enrolled 328 participants across 15 sites.
Detailed Summary
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil versus placebo in Korean adults with essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionJan 2016
Study CompletionFeb 2016
TodayJul 2026
First PostedJul 30, 2014
Enrollment StartJul 1, 2014
Primary CompletionJan 1, 2016
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.9 years ago
Interventions
Azilsartan medoxomildrug
Azilsartan medoxomil tablets
Azilsartan medoxomil placebodrug
Azilsartan medoxomil placebo-matching tablets